VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (1948)	8/12/1997 3:20:00 AM
From: T. Mann	of 9719

Being infected with influenza and being sick is not quite the same. I suspect that the difference in the results between the Ayerst and Aviron trials can be at least partially explained by differences in patient populations. Influenza infection can be detected through objective measurements (viral shedding, fever, and, yes, weighing of nasal discharge, etc.) and through symptom scoring (headaches, malaise, etc) . Investigators are free to choose signs to monitor and how to interpret the results. Obviously, 6-18 months old are not as good as older children in describing their symptoms or voluntarily giving their nasal discharge so it is conceivable that similar results were reported and/or interpreted differently. I think I should stop picking on AVIR (former Vector). All in all, it looks like a good story. However, years with biotech industry and biotech stocks tought my to be paranoidal and distrustful of companies' press releases. I will feel better when I see the data presented in a peer reviewed journal or at some conference. And then, IMHO, there will be plenty of opportunities to buy AVIR stock between $15 and $40. T.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next